Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 704289, 8 pages
http://dx.doi.org/10.1155/2014/704289
Clinical Study

Long-Term Effects and Prognosis in Acute Heart Failure Treated with Tolvaptan: The AVCMA Trial

1Department of Cardiology and Hematology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan
2Department of Cardiology, Ohara Medical Center, Fukushima 960-0195, Japan
3Second Department of Medicine, Shirakawa Kosei General Hospital, Shirakawa 961-0005, Japan
4Department of Cardiology, Fukushima Red Cross Hospital, Fukushima 960-8530, Japan
5First Department of Internal Medicine, Yamagata University School of Medicine, Yamagata 990-9585, Japan

Received 13 May 2014; Revised 28 August 2014; Accepted 8 September 2014; Published 10 November 2014

Academic Editor: James Kirkpatrick

Copyright © 2014 Satoshi Suzuki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. A. Hunt, W. T. Abraham, M. H. Chin et al., “ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult : a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society,” Circulation, vol. 112, no. 1, pp. e154–e235, 2005. View at Google Scholar
  2. W. J. Remme and K. Swedberg, “Guidelines for the diagnosis and treatment of chronic heart failure,” European Heart Journal, vol. 22, no. 17, pp. 1527–1560, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. M. M. Redfield, “Heart failure—an epidemic of uncertain proportions,” The New England Journal of Medicine, vol. 347, no. 18, pp. 1442–1444, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. W. F. Peacock, M. R. Costanzo, T. de Marco et al., “Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry,” Cardiology, vol. 113, no. 1, pp. 12–19, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Gheorghiade, W. T. Abraham, N. M. Albert et al., “Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry,” European Heart Journal, vol. 28, no. 8, pp. 980–988, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Cotter, J. Weissgarten, E. Metzkor et al., “Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure,” Clinical Pharmacology and Therapeutics, vol. 62, no. 2, pp. 187–193, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. H. M. Abdel-Qadir, J. V. Tu, L. Yun, P. C. Austin, G. E. Newton, and D. S. Lee, “Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization,” The American Heart Journal, vol. 160, no. 2, pp. 264–271, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Eshaghian, T. B. Horwich, and G. C. Fonarow, “Relation of loop diuretic dose to mortality in advanced heart failure,,” The American Journal of Cardiology, vol. 97, no. 12, pp. 1759–1764, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Sato, K. Kajimoto, T. Keida et al., “Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND registry),” Circulation Journal, vol. 77, no. 4, pp. 944–951, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Sato, K. Kajimoto, K. Asai et al., “Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data,” American Heart Journal, vol. 159, no. 6, pp. 949.e1–955.e1, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Nomura, N. Kurobe, Y. Mori et al., “Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure - COMPASS: Carperitide effects observed through monitoring dyspnea in acute decompensated heart failure study,” Circulation Journal, vol. 72, no. 11, pp. 1777–1786, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Hata, Y. Seino, T. Tsutamoto et al., “Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study,” Circulation Journal, vol. 72, no. 11, pp. 1787–1793, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. L. C. Costello-Boerrigter, W. B. Smith, G. Boerrigter et al., “Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure,” The American Journal of Physiology—Renal Physiology, vol. 290, no. 2, pp. F273–F278, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Gheorghiade, M. A. Konstam, J. C. Burnett Jr. et al., “Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials,” Journal of the American Medical Association, vol. 297, no. 12, pp. 1332–1343, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Suzuki, A. Yoshihisa, T. Yamaki et al., “Acute Heart Failure Volume Control Multicenter Randomized (AVCMA) Trial: comparison of tolvaptan and carperitide,” Journal of Clinical Pharmacology, vol. 53, no. 12, pp. 1277–1285, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. K. F. Adams Jr., G. C. Fonarow, C. L. Emerman et al., “Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE),” The American Heart Journal, vol. 149, no. 2, pp. 209–216, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Metra, S. Nodari, G. Parrinello et al., “Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance,” European Journal of Heart Failure, vol. 10, no. 2, pp. 188–195, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. D. E. Forman, J. Butler, Y. Wang et al., “Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure,” Journal of the American College of Cardiology, vol. 43, no. 1, pp. 61–67, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. M. R. Cowie, M. Komajda, T. Murray-Thomas, J. Underwood, and B. Ticho, “Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH),” European Heart Journal, vol. 27, no. 10, pp. 1216–1222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Butler, D. E. Forman, W. T. Abraham et al., “Relationship between heart failure treatment and development of worsening renal function among hospitalized patients,” American Heart Journal, vol. 147, no. 2, pp. 331–338, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Sezai, M. Hata, T. Niino et al., “Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting: The NU-HIT (Nihon University Working Group Study of Low-Dose hANP Infusion Therapy during Cardiac Surgery) trial for CKD,” Journal of the American College of Cardiology, vol. 58, no. 9, pp. 897–903, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Okawa, H. Horimoto, S. Mieno, Y. Nomura, M. Yoshida, and S. Sasaki, “Preischemic infusion of alpha-human atrial natriuretic peptide elicits myoprotective effects against ischemia reperfusion in isolated rat hearts,” Molecular and Cellular Biochemistry, vol. 248, no. 1-2, pp. 171–177, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Wakui, “Experimental study on myocardial protection by adjunct use of carperitide (hANP) in cardiac surgery,” Annals of Thoracic and Cardiovascular Surgery, vol. 11, no. 1, pp. 12–20, 2005. View at Google Scholar · View at Scopus